Business
Benitec Biopharma Releases Q3 2022 Financial Results
HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene
About this update from Benitec Biopharma Inc.
[{"type":"text","content":"HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (\"ddRNAi\") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exchange Commission. “With our key submission to the Central Ethics Committee in France completed in April, we are well-positioned to begin the clinical development program this year,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma. “The Benitec team remains committed to initiating the clinical development program for BB-301 and improving the lives of patients suffering from OPMD.” Operational Updates The key milestones related to the investigational agent under development by the Company and other corporate updates are outlined below: BB-301 Clinical Development Program Overview: The BB-301 clinical development program will be conducted in France, Canada, and the United States, and the primary elements of the clinical development plan are summarized below. The Clinical development plan will begin in 2022 and comprise approximately 76 weeks of follow-up: 6 month pre-treatment observation periods for the evaluation of baseline disposition and natural history of OPMD-derived dysphagia in each study participant.1 day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.52 weeks of post-dosing follow-up for conclusive evaluation of the primary and secondary endpoints of the Phase 1b/2a BB-301 treatment study. The OPMD Natural History (NH) Study will facilitate the characterization of OPMD patient disposition at baseline and assess subsequent rates of progression of dysphagia (swallowing impairment) via the use of the following quantitative radiographic measures of global swallowing function and pharyngeal constrictor muscle function inclusive of Videofluoroscopic Swallowing Studies (VFSS): Total Pharyngeal Residue %(C2-4)2Pharyngeal Area at Maximum Constriction (PhAMPC)Dynamic Imaging Grade of Swallowing Toxicity Scal...